Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Open-label Trial of Trilaciclib Prior to Chemotherapy Plus Tislelizumab as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

NCT05900921 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT05900921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05900921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Open-label Trial of Trilaciclib Prior to Chemotherapy Plus Tislelizumab as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
Lead sponsor
Sichuan University
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2023
Completion date
December 31, 2025
Enrollment
132 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced squamous non-small-cell lung cancer